Compare AbCellera Biologics Inc (ABCL) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs NRG Energy Inc — how do they compare? AbCellera Biologics Inc trades at $9.45 (market cap $2.99B), while NRG Energy Inc trades at $121.8 (market cap $24.83B). The key difference: NRG Energy Inc is far larger — about 8.3× AbCellera Biologics Inc's market cap, and NRG Energy Inc pays a 1.61% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NRG | |
|---|---|---|
Market Cap | $2.99B | $24.83B |
Sector | Health | Utilities |
52-Week High | $9.76 | $184.03 |
52-Week Low | $2.78 | $117.04 |
Enterprise Value | $2.58B | $48.79B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
NRG Energy trades at $118.91, down 0.66% today, with a bearish technical signal. Recent Q2 2026 earnings missed estimates, but revenue grew 11% year-over-year. The company is expanding with a 1.2 GW Texas data-center power project, targeting long-term EBITDA growth. Valuation metrics show a P/E of 30.76 and P/S of 0.72, with strong ROE at 26.77% but modest net income margin of 2.56%. Cash flow trends are volatile, with 2025 net cash flow at $3.83B but a projected decline in 2026.
Outlook: Growth driven by data-center demand and strategic acquisitions offers upside, but high debt and earnings misses pose risks. Analyst consensus is bullish with a $207.83 price target, though technical weakness and rising interest costs require caution. Key opportunities include hyperscaler partnerships, while risks involve leverage and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
